Safety Behavior Fading Versus Progressive Muscle Relaxation for Appearance Concerns
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorFlorida State University
About this trial
The current study aims to explore the efficacy of a text message based safety behavior fading intervention compared to a progressive muscle relaxation intervention for appearance concerns.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
being between the ages of 18 and 65 years old
having an internet-capable smart-phone
scoring at or above the empirical cutoff for appearance concerns measured by the Social Appearance Anxiety Scale (i.e., 52)
Disqualifiers
changes in psychotropic medication in the last 4 weeks
failing attention checks in baseline data collection
Trial design
Design model
Parallel
Treatments tested in this trial
Safety Behavior Fading for Appearance Concerns
BehavioralParticipants are asked to reduce or eliminate safety behaviors via text message reminders and checklists to monitor progress.
Progressive Muscle Relaxation
BehavioralParticipants are asked to practice relaxation daily via text message reminder and checklists to monitor progress.
Treatment groups
300 Participants
are divided into 2 treatment groupsGroup A: Safety Behavior FadingExperimental treatment 1 intervention
Group B: Progressive Muscle RelaxationActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
The Social Appearance Anxiety Scale (SAAS)
Self-report scale that measures appearance anxiety symptoms. Scores range from 16 to 80 with higher scores indicating higher levels of appearance concerns.
Time frame
Day 0, Day 28, Day 562
Appearance Behaviors Checklist past-week version (author constructed)
Self-report scale used to measure frequency of engaging in appearance-related safety behaviors. This scale will be used as a manipulation check. Each item is rated on a 0 to 10 scale. Total scores range from 0 to 130 with higher scores indicating greater engagement in appearance-related safety behaviors
Time frame
Day 0, Day 28, Day 563
Appearance Anxiety Inventory (AAI; Veale et al., 2014)
Self-report scale that measures of body dysmorphic symptoms. Scores range from 0 to 40 with higher scores indicating higher levels of body dysmorphic symptoms.
Time frame
Day 0, Day 28, Day 564
Social Phobia Inventory (SPIN; Connor et al., 2000)
Self-report scale that measures social anxiety symptoms. Scores range from 0 to 68 with higher scores indicating higher levels of social anxiety.
Time frame
Day 0, Day 28, Day 56Secondary outcomes
1
Center for Epidemiologic Studies Depression Scale-10 (CESD; Andreson, 1994)
Self-report measure of depression symptom severity. Each item is rated on a 0 to 3 scale. Total scores range from 0 to 30 with higher scores indicating greater depression severity.
Time frame
Day 0, Day 28, Day 562
Generalized Anxiety Disorder-7 (GAD-7; Spitzer et al., 2006)
Self-report measure of anxiety symptom severity. Each item is rated on a 0 to 3 scale. Total scores range from 0 to 28 with higher scores indicating greater anxiety severity.
Time frame
Day 0, Day 28, Day 563
Appearance Preference Task
Computerized forced-choice task measuring appearance importance relative to other favorable characteristics. The APT randomly presents a series of 33 word pairs and asks the participant to select the concept that is more important to them. Each pair consists of a positive appearance-related adjective and a positive character trait unrelated to appearance (e.g., beautiful-responsible). Higher scores indicate greater endorsement of appearance words.
Time frame
Day 0, Day 28, Day 564
Social Interaction Scale (Author Constructed)
Single-item self-report scale that the extent to which individuals engage with their social support networks. This question asks: "what percentage of your time awake did you spend interacting with others this past week (0% =No time at all, 100% =all of the time)?"
Time frame
Day 0, Day 28, Day 56Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov